Whitehawk Therapeutics (WHWK) executive awarded 51,020 shares in Form 4 filing

Rhea-AI Filing Summary

Whitehawk Therapeutics executive Bryan Ball reported a stock-based compensation grant on Common Stock. On May 14, 2026, he acquired 51,020 shares at an indicated value of $3.92 per share as a grant or award, rather than an open-market purchase. Following this award, his direct holdings in Whitehawk Therapeutics increased to 448,126 Common Stock shares, reflecting a routine compensation-related equity grant instead of a discretionary market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BALL BRYAN

Role See remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	51,020	$3.92	$200K

Holdings After Transaction: Common Stock — 448,126 shares (Direct, null)

Footnotes (1)

Key Figures

Shares granted: 51,020 shares Grant price: $3.92 per share Total holdings after grant: 448,126 shares

3 metrics

Shares granted 51,020 shares Common Stock grant on May 14, 2026

Grant price $3.92 per share Indicated value for Common Stock award

Total holdings after grant 448,126 shares Direct Common Stock ownership following transaction

Key Terms

Form 4, grant or award acquisition, non-derivative, Common Stock

4 terms

Form 4 regulatory

"Bryan Ball reported a stock-based compensation grant on Common Stock."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

grant or award acquisition financial

"The transaction is coded as a grant or award acquisition, meaning it is compensation-related."

non-derivative financial

"The reported transaction involves non-derivative Common Stock only."

Common Stock financial

"He acquired 51,020 shares at an indicated value of $3.92 per share as a grant."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BALL BRYAN

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		51,020	A	$3.92	448,126	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Chief Technical Operations Officer

	/s/ Stephen Rodin, as Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Bryan Ball report for Whitehawk Therapeutics (WHWK)?

Bryan Ball reported receiving a grant of 51,020 shares of Whitehawk Therapeutics Common Stock. The transaction is coded as a grant or award acquisition, meaning it is compensation-related rather than an open-market purchase or sale.

At what price was Bryan Ball’s WHWK stock grant valued?

The 51,020-share grant to Bryan Ball was valued at $3.92 per share. This figure reflects the transaction price per share used for the award, not a price paid in an open-market purchase.

How many Whitehawk Therapeutics (WHWK) shares does Bryan Ball hold after this transaction?

After the grant, Bryan Ball directly holds 448,126 shares of Whitehawk Therapeutics Common Stock. This total includes the 51,020 shares received in the reported compensation-related award.

Was Bryan Ball’s WHWK Form 4 transaction a market buy or sell?

The Form 4 shows a grant or award acquisition, not a market buy or sell. The transaction code “A” indicates shares were awarded as compensation rather than purchased or sold on the open market.

Does the Bryan Ball Form 4 for WHWK involve derivative securities or options?

The reported transaction involves non-derivative Common Stock only. The derivative summary in the data is empty, indicating no options, warrants, or other derivative securities are reported in this filing.